BIONYSELaboratory Analytical InstrumentsFiscal year ends December 31Also trades as BIO.B
BIO-RAD LABORATORIES, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$352.82−0.88 (-0.25%)
Close on Oct 19, 2026
- Market cap
- $9.46B
- P/E (TTM)
- 42.8
- Dividend yield
- –
BIO-RAD LABORATORIES, INC. revenue by segment
By business segment
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Clinical Diagnostics | $1.58B | $1.57B | $1.56B | $1.53B | $1.53B | $1.53B | $1.54B | $1.53B | $1.51B | $1.51B | $1.49B | $1.47B | 61.0% | +3.4% |
| Life Science | $1.01B | $1.02B | $1.02B | $1.03B | $1.03B | $1.02B | $1.03B | $1.04B | $1.05B | $1.10B | $1.18B | $1.25B | 39.0% | -1.7% |
| All Other Segments [Member] | – | – | $0 | $0 | $0 | $0 | $500.00K | $1.50M | $2.00M | $2.80M | $3.50M | $3.30M | – | – |
By product or service
By region
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $999.40M | $1.01B | $1.02B | $1.04B | $1.04B | $1.03B | $1.04B | $1.05B | $1.05B | $1.08B | $1.12B | $1.17B | 38.6% | -4.2% |
| Europe [Member] | $900.80M | $888.80M | $881.80M | $860.90M | $844.40M | $833.70M | $834.10M | $823.10M | $810.50M | $815.20M | $819.80M | $824.70M | 34.8% | +6.7% |
| Asia Pacific [Member] | $515.00M | $519.60M | $513.30M | $497.90M | $503.80M | $508.60M | $521.60M | $539.40M | $531.40M | $543.20M | $563.00M | $566.80M | 19.9% | +2.2% |
| Americas [Member] | $174.10M | $170.70M | $165.40M | $162.00M | $163.10M | $168.60M | $169.30M | $171.20M | $175.00M | $167.60M | $166.50M | $161.30M | 6.7% | +6.7% |
From the segment and revenue-disaggregation notes of Bio-Rad Laboratories's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.